Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $1.11 million. The enterprise value is $657,007.
| Market Cap | 1.11M |
| Enterprise Value | 657,007 |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SLXN has 418,995 shares outstanding.
| Current Share Class | 418,995 |
| Shares Outstanding | 418,995 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.67% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 4.53% |
| Float | 414,619 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.01 |
| P/TBV Ratio | 3.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 6.84.
| Current Ratio | 1.00 |
| Quick Ratio | 0.59 |
| Debt / Equity | 6.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6,365.50 |
Financial Efficiency
Return on equity (ROE) is -897.46% and return on invested capital (ROIC) is -190.63%.
| Return on Equity (ROE) | -897.46% |
| Return on Assets (ROA) | -123.27% |
| Return on Invested Capital (ROIC) | -190.63% |
| Return on Capital Employed (ROCE) | -2,348.89% |
| Weighted Average Cost of Capital (WACC) | 1.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$922,143 |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SLXN has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.79% in the last 52 weeks. The beta is -0.26, so SLXN's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | -97.79% |
| 50-Day Moving Average | 3.80 |
| 200-Day Moving Average | 17.49 |
| Relative Strength Index (RSI) | 35.80 |
| Average Volume (20 Days) | 70,389 |
Short Selling Information
The latest short interest is 13,737, so 3.28% of the outstanding shares have been sold short.
| Short Interest | 13,737 |
| Short Previous Month | 16,557 |
| Short % of Shares Out | 3.28% |
| Short % of Float | 3.31% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.73M |
| Pretax Income | -12.91M |
| Net Income | -12.91M |
| EBITDA | -12.72M |
| EBIT | -12.73M |
| Earnings Per Share (EPS) | -$63.78 |
Balance Sheet
The company has $2.41 million in cash and $1.99 million in debt, with a net cash position of $424,000 or $1.01 per share.
| Cash & Cash Equivalents | 2.41M |
| Total Debt | 1.99M |
| Net Cash | 424,000 |
| Net Cash Per Share | $1.01 |
| Equity (Book Value) | 291,000 |
| Book Value Per Share | 0.86 |
| Working Capital | 5,000 |
Cash Flow
In the last 12 months, operating cash flow was -$12.01 million and capital expenditures -$3,000, giving a free cash flow of -$12.02 million.
| Operating Cash Flow | -12.01M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 12,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.02M |
| FCF Per Share | -$28.68 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1,194.26% |
| FCF Yield | -1,111.46% |
Analyst Forecast
The average price target for SLXN is $60.00, which is 2,172.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.00 |
| Price Target Difference | 2,172.73% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 29, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 29, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |